Sanofi-Aventis Pharma S.A. Withdraws Its Application For An Extension Ofindication For Taxotere And Docetaxel Winthrop (docetaxel)

The European Medicines Agency (EMEA) has been formally notified by Sanofi-Aventis Pharma S.A. of its decision to withdraw its application for an extension of indication for the centrally authorised medicines Taxotere (docetaxel) 20 mg/0.5 ml and 80 mg/2 ml, concentrate and solvent for solution for infusion and Docetaxel Winthrop (docetaxel) 20 mg/0.5 ml and 80 mg/2 ml, concentrate and solvent for solution for infusion.

More: continued here

Filed under: Breast Cancer on November 21st, 2008